Evidence map›Paper›PMID 37577522›Full record

ArticlebioRxiv : the preprint server for biology2023

A fibroblast-dependent TGFβ1/sFRP2 noncanonical Wnt signaling axis underlies epithelial metaplasia in idiopathic pulmonary fibrosis.

Max L Cohen, Alexis N Brumwell, Tsung Che Ho, Genevieve Montas, Jeffrey A Golden, Kirk D Jones, Paul J Wolters, Ying Wei, Harold A Chapman, Claude J Le Saux

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Max L CohenDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Alexis N BrumwellDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Tsung Che HoDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Genevieve MontasDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Jeffrey A GoldenDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Kirk D JonesDepartment of Pathology; University of California San Francisco, San Francisco, California.
Paul J WoltersDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Ying WeiDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Harold A ChapmanDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
Claude J Le SauxDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; University of California San Francisco, San Francisco, California.
University of California, San Francisco · US

Funding

MUTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007185 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle, LAURENCE HUANG · 1985 to 2026
$24.6M
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damageU01HL134766 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAPMAN, HAROLD A, KOTTON, DARRELL N. · 2016 to 2022
$8.1M
Program to promote lung regeneration and block fibrosisR35HL150767 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAPMAN, HAROLD A · 2020 to 2025
$5.8M
Reprogramming of type 2 alveolar epithelial cells in idiopathic pulmonary fibrosis and regulation by TGFb1.F32HL156356 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COHEN, MAX LOUIS · 2021 to 2023
$189k
NHLBI NIH HHS F32 HL156356NHLBI NIH HHS R35 HL150767NHLBI NIH HHS T32 HL007185NHLBI NIH HHS U01 HL134766
6 · The paper itself

Abstract

Reciprocal interactions between alveolar fibroblasts and epithelial cells are crucial for lung homeostasis, injury repair, and fibrogenesis, but underlying mechanisms remain unclear. To investigate this, we administered the fibroblast-selective TGFβ1 signaling inhibitor, epigallocatechin gallate (EGCG), to Interstitial Lung Disease (ILD) patients undergoing diagnostic lung biopsy and conducted single-cell RNA sequencing on spare tissue. Unexposed biopsy samples showed higher fibroblast TGFβ1 signaling compared to non-disease donor or end-stage ILD tissues. In vivo, EGCG significantly downregulated TGFβ1 signaling and several pro-inflammatory and stress pathways in biopsy samples. Notably, EGCG reduced fibroblast secreted Frizzle-like Receptor Protein 2 (sFRP2), an unrecognized TGFβ1 fibroblast target gene induced near type II alveolar epithelial cells (AEC2s). In human AEC2-fibroblast coculture organoids, sFRP2 was essential for AEC2 trans-differentiation to basal cells. Precision cut lung slices (PCLS) from normal donors demonstrated that TGFβ1 promoted KRT17 expression and AEC2 morphological change, while sFRP2 was necessary for KRT5 expression in AEC2-derived basaloid cells. Wnt-receptor Frizzled 5 (Fzd5) expression and downstream calcineurin-related signaling in AEC2s were required for sFRP2-induced KRT5 expression. These findings highlight stage-specific TGFβ1 signaling in ILD, the therapeutic potential of EGCG in reducing IPF-related transcriptional changes, and identify the TGFβ1-non-canonical Wnt pathway crosstalk via sFRP2 as a novel mechanism for dysfunctional epithelial signaling in Idiopathic Pulmonary Fibrosis/ILD.

Identifiers

PMID37577522
PMCPMC10418166
OpenAlexW4385606678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.